Ustekinumab Biosimilars
Ustekinumab is a fully human IgG1k monoclonal antibody that binds with high affinity and specificity to the p40 subunit of interleukins (IL-) 12 and 23, inhibiting their activity by preventing binding to their receptors. The European extension of the patent (Supplementary Protection Certificate) of...
Saved in:
Main Authors: | Elena Carmona-Rocha, Lluís Puig |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-11-01
|
Series: | Biologics |
Subjects: | |
Online Access: | https://www.mdpi.com/2673-8449/4/4/25 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
by: Steven R. Feldman, et al.
Published: (2024-12-01) -
A case of ustekinumab-induced pustular psoriasis was treated with IL-17A inhibitor
by: LIN Junjie, et al.
Published: (2024-11-01) -
Efficacy and safety of ustekinumab in the treatment of moderate to severe plaque psoriasis in Singapore
by: Wai Sze Agnes Chan, et al.
Published: (2023-07-01) -
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2024-10-01) -
A review of biosimilars in psoriasis: impacts on efficacy, safety, access, and a first-hand look at biosimilar cost savings within the department of veterans affairs
by: Rebecca Reese, et al.
Published: (2024-12-01)